Idera Pharmaceuticals (NasdaqCM:IDRA) - Share price, News & Analysis

IDRA fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

IDRA Stock Overview

Idera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for rare disease indications in the United States.

Risk Analysis

Makes less than USD$1m in revenue ($0)

Volatile share price over the past 3 months

Shareholders have been diluted in the past year

Does not have a meaningful market cap ($28M)

Idera Pharmaceuticals Competitors

Fate Therapeutics

NasdaqGM:FATE

US$2.2b

Northwest Biotherapeutics

OTCPK:NWBO

US$688.6m

AVEO Pharmaceuticals

NasdaqCM:AVEO

US$138.3m

Pieris Pharmaceuticals

NasdaqCM:PIRS

US$133.4m

Price History & Performance

Summary of all time highs, changes and price drops for Idera Pharmaceuticals
Historical stock prices
Current Share Price	US$0.52
52 Week High	US$1.71
52 Week Low	US$0.29
Beta	1.54
1 Month Change	8.35%
3 Month Change	6.84%
1 Year Change	-54.77%
3 Year Change	-79.76%
5 Year Change	-95.96%
Change since IPO	-99.99%

Recent News & Updates

May 11

We Think Idera Pharmaceuticals (NASDAQ:IDRA) Needs To Drive Business Growth Carefully

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

Shareholder Returns

	IDRA	US Biotechs	US Market
7D	48.3%	1.4%	-2.7%
1Y	-54.8%	-21.7%	-12.9%

Return vs Industry: IDRA underperformed the US Biotechs industry which returned -22.1% over the past year.

Return vs Market: IDRA underperformed the US Market which returned -12.7% over the past year.

Price Volatility

Is IDRA's price volatile compared to industry and market?
IDRA volatility
IDRA Average Weekly Movement	12.7%
Biotechs Industry Average Movement	12.4%
Market Average Movement	7.9%
10% most volatile stocks in US Market	16.9%
10% least volatile stocks in US Market	3.0%

Stable Share Price: IDRA is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.

Volatility Over Time: IDRA's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

Founded	Employees	CEO	Website
1989	13	Vinnie, Vin Milano	https://www.iderapharma.com

Idera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for rare disease indications in the United States. It offers Tilsotolimod (IMO-2125), a synthetic phosphorothioate oligonucleotide that acts as a direct agonist of TLR9 to stimulate the immune systems and for treating solid tumors, squamous cell carcinoma of the head and neck, and colorectal cancer. The company has a collaboration agreement with Bristol-Meyers Squibb.

Idera Pharmaceuticals Fundamentals Summary

How do Idera Pharmaceuticals's earnings and revenue compare to its market cap?
IDRA fundamental statistics
Market Cap	US$27.55m
Earnings (TTM)	-US$16.84m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-1.6x

P/E Ratio

Is IDRA overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
IDRA income statement (TTM)
Revenue	US$0
Cost of Revenue	US$9.25m
Gross Profit	-US$9.25m
Other Expenses	US$7.60m
Earnings	-US$16.84m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)	-0.32
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did IDRA perform over the long term?

See historical performance and comparison

Valuation

Is Idera Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry

1.07x

Price to Book (PB) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate IDRA's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate IDRA's fair value for valuation analysis.

Price To Earnings Ratio

PE vs Industry: IDRA is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: IDRA is unprofitable, so we can't compare its PE Ratio to the US market.

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate IDRA's PEG Ratio to determine if it is good value.

Price to Book Ratio

PB vs Industry: IDRA is good value based on its PB Ratio (1.1x) compared to the US Biotechs industry average (1.5x).

Future Growth

How is Idera Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

Future Growth Score

0/6

Future Growth Score 0/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

11.1%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if IDRA's forecast earnings growth is above the savings rate (1.9%).

Earnings vs Market: Insufficient data to determine if IDRA's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if IDRA's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if IDRA's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if IDRA's Return on Equity is forecast to be high in 3 years time

Past Performance

How has Idera Pharmaceuticals performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

23.2%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: IDRA is currently unprofitable.

Growing Profit Margin: IDRA is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: IDRA is unprofitable, but has reduced losses over the past 5 years at a rate of 23.2% per year.

Accelerating Growth: Unable to compare IDRA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: IDRA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).

Return on Equity

High ROE: IDRA has a negative Return on Equity (-84.45%), as it is currently unprofitable.

Financial Health

How is Idera Pharmaceuticals's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: IDRA's short term assets ($29.4M) exceed its short term liabilities ($3.8M).

Long Term Liabilities: IDRA's short term assets ($29.4M) exceed its long term liabilities ($494.0K).

Debt to Equity History and Analysis

Debt Level: IDRA is debt free.

Reducing Debt: IDRA has no debt compared to 5 years ago when its debt to equity ratio was 0.5%.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: IDRA has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: IDRA has sufficient cash runway for 1.1 years if free cash flow continues to grow at historical rates of 6.3% each year.

Dividend

What is Idera Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate IDRA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate IDRA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if IDRA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if IDRA's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as IDRA has not reported any payouts.

Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

3.6yrs

Average management tenure

CEO

Vinnie, Vin Milano (57 yo)

7.42yrs

Tenure

US$1,134,433

Compensation

Mr. Vincent J. Milano, also known as Vinnie and Vin, has been an Independent Director of BioCryst Pharmaceuticals, Inc. since July 26, 2021. He has been an Independent Director at Aclaris Therapeutics, Inc...

CEO Compensation Analysis

Compensation vs Market: Vinnie, Vin's total compensation ($USD1.13M) is above average for companies of similar size in the US market ($USD771.97K).

Compensation vs Earnings: Vinnie, Vin's compensation has been consistent with company performance over the past year.

Leadership Team

Experienced Management: IDRA's management team is considered experienced (3.6 years average tenure).

Board Members

Experienced Board: IDRA's board of directors are considered experienced (6.3 years average tenure).

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 5.9%.

Data	Last Updated (UTC time)
Company Analysis	2022/05/21 00:00
End of Day Share Price	2022/05/20 00:00
Earnings	2022/03/31
Annual Earnings	2021/12/31